La Vista, Nebraska – Streck is excited to announce the release of MDx-Chex for RLP, the newest addition to the MDx-Chex^® line of molecular quality controls. MDx-Chex for RLP is a true patient-like, ready-to-use, full-process molecular quality control designed for your respiratory low plex assay verification.  

Each control contains intact, inactivated microorganisms suspended in a stabilized patient-like matrix, making them ideal for evaluating the entire molecular testing process from lysis to extraction to detection. Supplied in single-use vials, these controls cover Influenza A, Influenza B, Human Rhinovirus, Human Respiratory Syncytial Virus (RSV), SARS CoV-2, and S. pyogenes (Group A Strep), are instrument agnostic and can be stored at room temperature, helping labs achieve reliable performance, streamlined workflows and confident results.

“As respiratory testing sees increased demand globally, labs need quality controls that keep pace with their workflows. The addition of MDx-Chex for RLP strengthens our molecular control portfolio and reinforces our dedication to the laboratories we serve,” said Chris Connelly, Director of Business Segment – Molecular. “We’re committed to giving labs the tools they need to deliver reliable results across their respiratory panels.”  

Streck’s respiratory control launch marks the latest addition to Streck’s expanding MDx-Chex portfolio, reinforcing the company’s mission to ensure every test result is trusted.

MDx-Chex for RLP is for Research Use Only. Not for use in diagnostic procedures.  

About Streck, Inc.  Established in 1971, Streck provides solutions that ensure every result counts by empowering clinical and research laboratories to reliably deliver accurate results, advance diagnostics, and enable healthier, happier lives for patients everywhere. Streck products are manufactured in La Vista, Nebraska, and delivered to thousands of labs worldwide